Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

The present work describes the development of a hybrid and pH-responsive system for rifampicin using the clay mineral ‘montmorillonite’ as a nanocarrier. The influence of operational variables on the drug incorporation process was evaluated using 24 factorial designs. Under optimized conditions, the experiment allowed an incorporated drug dose equivalent to 98.60 ± 1.21 mg/g. Hybrid systems were characterized by different characterization techniques (FTIR, XRD, TGA, DSC, and SEM) to elucidate the mechanism of interaction between the compounds used. Through in vitro release studies, it was possible to verify the efficacy of the pH-dependent system obtained, with approximately 70% of the drug released after sixteen hours in simulated intestinal fluid. The adjustment of the experimental release data to the theoretical model of Higuchi and Korsmeyer–Peppas indicated that the release of rifampicin occurs in a prolonged form from montmorillonite. Elucidation of the interactions between the drug and this raw clay reinforces its viability as a novel carrier to develop an anti-TB/clay hybrid system with good physical and chemical stability.

Cite

CITATION STYLE

APA

Damasceno Junior, E., Barbosa, R. de M., da Silva, R. de C. D., Costa, F. dos S., da Silva, D. R., Viseras, C., … Fernandes, N. S. (2023). Montmorillonite–Rifampicin Nanohybrid for pH-Responsive Release of the Tuberculostatic. Pharmaceutics, 15(2). https://doi.org/10.3390/pharmaceutics15020512

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free